Introduction 75
Cancer progression results from uncontrolled migration of cells away from the primary 76 tumor, intravasation into lymphatic or vascular circulation, invasion into secondary tissues 77 and the formation of metastasized tumors (1, 2) which are the main cause of cancer-related 78 deaths (3-5). Migrating cells generate a driving force for cell motility based on the extension 79 of filipodia and lamellipodia using actin polymerization at the leading edges of the cell (6). 80
New approaches for enhancing cancer treatment by impairing cell migration and metastasis 81 might offer promise for curing patients with malignancies. Combinations of anticancer 82 therapeutic regimens that not only reduce cell proliferation but also limit metastasis would be 83 advantageous (7-9). 84
Herbal medicines are used in complementary and traditional medicines (10-12). 85
Traditional Chinese medicine (TCM) relies on natural product extracts containing complex 86 mixtures of components, suggested to deliver therapeutic benefit to individuals suffering 87 from non-small cell lung cancer, liver, breast, and colorectal cancers (12-14). The inherent 88 complexity of TCM suggests principle components might act in concert with adjuvant 89 components, explaining an apparent synergy in therapeutic benefits seen from the whole 90 extract as compared to individual compounds (15). Modulation of multiple regulatory 91 signaling targets has been proposed as essential for the anti-proliferative, anti-migratory and 92 anti-metastatic properties of TCMs (16, 17) . 93
Compound Kushen Injection (CKI) has been used in combination with chemotherapies such 94 as oxaliplatin and 5-fluorouracil in China since 1995 for the treatment of gastric, liver and 95 non-small cell lung carcinomas (18). Composed of alkaloids, flavonoids, organic acids 96 6 to analyse single compounds and confirm their concentrations in CKI. Fractionation of CKI 125 was done by using Shimadzu HPLC SPC-M20A photodiode-array UV-Vis detector (Japan) 126 equipped with a C 18 column (5 µm, 250 x 10 mm; Phenomenex, CA, USA), with methods for 127 fractionation and concentration determinations as described previously (23) Two-dimensional (2D) cell migration was measured using circular wound closure rates (24). 140 CKI-based and vehicle control treatments were applied in low serum DMEM, with the 141 mitotic inhibitor 5-fluoro-2'-deoxyuridine (FUDR). Initial wound areas were imaged at 0 h 142 (10x objective) with a Canon EOS 6D camera (Canon, Tokyo, Japan) on an Olympus 143 inverted microscope (Olympus Corp., Tokyo, Japan); XnConvert software was used to 144 standardize the images. NIH ImageJ software (U.S. National Institutes of Health, MD, USA) 145 was used to quantify wound areas at 0 h and at a second timepoint (18 to 24 h), set for each 146 cell line to ensure wounds were not completely closed. Experiments were independently 147 repeated three times, with four to eight replicates. 148 149 7
Transwell invasion assay 150
Invasion assays were performed in 24-well transwell inserts (6.5 mm, 8 μm pore size; 151 Corning ® Transwell polycarbonate; Sigma-Aldrich). The upper surface of the filter was 152 layered with extracellular matrix (ECM) gel from Sigma-Aldrich (at dilutions empirically 153 optimized for each cell line; Supplementary Table 2 
Apoptosis assay 181
Apoptosis assays based on annexin V and propidium iodide staining were performed as 182 described previously (17). Briefly, MDA-MB-231, HEK-293 and HFF cells were seeded in 183 6-well trays and treated with 2 mg/ml of CKI. After 24 h of treatment, cells were harvested, 184 and levels of apoptotic cells were measured using the Annexin V-FITC detection kit (Thermo 185
Fisher Scientific) according to the manufacturer's guidelines. Cells were acquired on a 186 LSRFortessa X-20 (BD Biosciences, NJ, USA) and data were analyzed using FlowJo 187 software (TreeStar Inc., OR, USA). 188 189
Live cell imaging 190
Cells in 96 well plates were cultured to 80 % confluency, then serum-starved for 12-18 h in 191 optimal culture media with 2 % FBS and 400 nM FUDR. Wounds were created as circular 192 lesions in the confluent monolayers, and treatments were added as described for the circular 193 wound closure assay above. Plates were placed in an enclosed humidified chamber at 37°C 194 with 5 % CO 2 for 20 h, and images were acquired at 15-min intervals with a Nikon Ti E Live 195 without CKI treatment (Fig 1 and Supplementary Fig 1) . Differences in gene expression 254 levels were used to identify migration related GO terms and pathways of interest, which were 255 classified by functional roles via GO and KEGG over-representation analyses. Enriched GO 256 terms connected to cell migration such as "positive regulation of locomotion", "tissue 257 migration "and "leucocyte migration" emerged from analyses of DE genes in CKI-treated 258 MDA-MB-231 cells ( Supplementary Fig 1 and Supplementary Data 1). Integration of DE 259 genes associated with CKI treatment into KEGG pathways showed that some of the most 260 over-represented pathways were "focal adhesion", "regulation of actin cytoskeleton", 261 "pathways in cancer", "TGF-β signaling pathway" and "adherens junction" (Fig 1) . These 262 results indicated that many of the genes affected by CKI treatment were involved in cell 263 migration-related pathways. 264 265
Identification of CKI components 266
CKI was fractionated and components were selectively recombined to create MJ and MN 267 fractions ( Supplementary Fig 2) as treatments for bioassays on cultured cells. Concentrations 268 of the nine major compounds in CKI were measured using LC-MS/MS (see Methods). The 269 concentrations of MJ components were determined ( Supplementary Figs 3 and 4 ) from 270 calibration curves of nine standard compounds as previously described (23) and 271 summarized in Supplementary Table 1 . The total concentration of the nine major 272 compounds in CKI was 9.99 mg/ml which accounted for approximately 40 % of the dry mass 273 of CKI, and the total concentration of the nine compounds in MJ was 8.62 mg/ml, indicating 274 that the major compounds were clearly fractionated from CKI, and that MJ and MN 275 components were well separated. 276
277

Impairment of cell migration by CKI and fractionated mixtures 278
Effects of CKI on two-dimensional cell migration were assessed using a circular wound 279 healing assay (Fig 2A) . Percent wound closure after 20 h was calculated based on the initial 280 wound area. CKI-based treatments were tested on eight different cancer cell lines (HT-29, 281 SW-480, DLD-1, U-87 MG, U-251 MG and MDA-MB-231) and two non-cancerous cell 282 lines (HEK-293 and HFF), at five doses ranging from 0 to 2 mg/ml ( Fig 2B) . In all cell lines, 283 net migration rates were inhibited more by CKI than by MN or MJ treatments alone, except 284 in HEK-293 which showed low sensitivity to CKI. The retention of biological activity in the 285 fractionated MJ and MN treatments was confirmed by demonstrating reconstituted CKI (in 286 which MN and MJ were mixed together) was equally effective as CKI for blocking cell 287 migration ( Fig 2B) . The most sensitive cell lines were breast cancer (MDA-MB-231) and 288 colon cancer (HT-29). DLD-1 and HEK-293 cell lines were the least sensitive. 289
290
In all the CKI-sensitive cell lines, the inhibition of migration by MN alone was greater than 291 that seen with MJ alone ( Fig 2B) , but neither treatment was as potent as CKI in any cell line. 292
To determine if a single compound in MJ accounted for the enhanced inhibition seen with co-293 application of MJ and MN, each of the isolated major compounds alone was added in turn to 294 1 mg/ml MN, at a final concentration equal to its original concentration in 2 mg/ml CKI. 295
Wound healing assays showed certain compounds added to MN produced a significantly 296 greater inhibition than MN alone, but the effective compounds and levels of potency differed 297 between cell lines ( Fig 2C and Supplementary Fig 5) . Matrine was effective in MDA-MB-298 231, HT-29 and U-251 MG cell lines; sophocarpine was effective in HEK-293; trifolirhizin 299 13 was effective in HT-29, SW-480 and U-251 MG; and adenine was effective in HT-29 cells, 300 as determined by a significant decrease in migration as compared to MN alone. More than 301 one compound in MJ appeared to contribute to the activity of CKI in blocking cell migration. 302 303 None of the CKI-based treatments induced significant cytotoxicity at 1 or 2 mg/ml, as 304 assessed by Alamar Blue assays ( Figs 3A, B , C). The lack of cytotoxicity suggested that the 305 observed impairment of the two-dimensional cell migration was not an indirect consequence 306 of reduced cell viability. However, CKI at 2 mg/ml substantially increased apoptosis in 307 MDA-MB-231 and moderately increased apoptosis in HEK-293 cells, without a significant 308 effect on HFF (Figs 3D, E, F, G). These data extend prior work which showed CKI increased 309 apoptosis in MCF-7 breast cancer cells (Qu et al., 2016) , and support the idea that multiple 310 responses induced by CKI could contribute to its overall anti-cancer effects. 311
312
To quantify the effects of CKI on two-dimensional cell motility in vitro in more detail, 313 trajectories of individual cells were monitored in real time using live cell imaging (Fig 4) . 314
Vehicle-treated cells were compared with those treated with 2 mg/ml CKI, or 1 mg/ml MN 315 or MJ (doses equal to their concentration in CKI). Data were compiled for representative 316 cells from six cancer and two non-cancerous cell lines. Positions of individual cells as a 317 function of time over 20 h were determined by the location of the cell nucleus ( Fig 4A) . 318
Distances moved per unit time interval showed a Gaussian distribution; the peak position 319 illustrates the mean distance travelled per increment. Significant displacement of the curve to 320 the left (representing a decreased mean distance travelled per time interval) was evident for 321 CKI treatment in all cell lines as compared to vehicle-treated controls ( Fig 4B, and  322 Supplementary video). Significant reductions in mean distance by either MN or MJ were 323 observed in HT-29 and SW-480 cells. Reductions in mean distance by MN but not MJ were 324 14 seen in U-87 MG, MDA-MB-231 and HFF cells. U-251 MG and DLD-1 cancer cells 325 responded only to whole CKI. The effectiveness of CKI in blocking migration depended on 326 the simultaneous presence of multiple minor and major compounds, but the specific agents 327 conferring anti-migration activity appeared to depend on the cell line. 328 329
Impairment of invasiveness by CKI treatments in cancer and non-cancer cell lines 330
A transwell Boyden chamber assay with ECM-coated filters was used to measure the 331 invasiveness of cells in response to a serum chemoattractant gradient in vehicle control, CKI, 332 MN, and MJ treatment conditions ( Fig 5) . CKI treatment and the combined MN+MJ 333 treatment (i.e., reconstituted CKI) both significantly reduced invasiveness in all cell types. 334
Smaller but significant decreases in invasiveness were seen with MN alone in all cell types 335 except SW-480 and were seen with MJ alone in all but SW-480 and MDA-MB-231 cell lines. 336
These results suggested that a combination of major and minor components of CKI was 337 required for maximal inhibition of invasiveness through extracellular matrix barriers. 338
Transcriptome analysis of MDA-MB-231 cells treated with CKI 339
Functional enrichment analysis was used to narrow the field of candidate mechanisms 340 potentially associated with the anti-migratory effects of CKI. Perturbations of KEGG 341 Pathways that were significantly over-represented in DE genes affected by CKI treatment 342 were further analysed using SPIA ( Fig 6A and Supplementary Data 2) . "Melanogenesis", 343 "TGF-β signaling pathway", "focal adhesion", "regulation of actin cytoskeleton", "ErbB 344 signaling pathway", and "GnRH signaling pathway" were significantly perturbed based on 345 'global perturbation values' (pG<0.05), consistent with the results of the KEGG analysis. 346
Together, these analyses provided evidence that CKI was likely to impair cell migration by 347 altering both adhesion and motility (Figs 6B and C). To explore this idea, genes from two 348 strongly affected pathways ("focal adhesion" and "actin cytoskeleton") were characterised by 349 15 comparing three independent gene datasets: (i) a set containing 135 Tumor Alterations 350
Relevant for Genomics driven Therapy (TARGET) genes; (ii) a set containing 140 migration 351 related genes collected from published articles; and (iii) a set containing 1381 genes from 352 KEGG pathways. We identified 14 clinically relevant DE genes, which were: CTNNB1, 353 CDH1, AKT1, AKT2, AKT3, CCND1, MAPK1, JAK2, APC, CDK4, RB1, PIK3CA, and 354 PTEN, all of which have been shown to affect cell migration (Fig 6D, Supplementary Table 3  355 and Supplementary Data 3) , suggesting that the slowing of cell migration could be clinically 356 relevant to CKI treatment outcomes. 357
358
CKI interrupts F-actin polymerization 359
The results of functional enrichment analysis highlighted the actin cytoskeleton and focal 360 adhesion pathways as potential targets of CKI. As a result, we decided to examine the effect 361 of CKI on F-actin polymerization, filopodia formation and lamellipodia extension using 362 confocal microscopy in all eight cell lines (Fig 7) . Cells in all lines treated with CKI, MN 363 and MJ (at doses equal to those in 2 mg/ml CKI) at 24 h were smaller and lacked cellular 364 processes such as lamellipodia as compared to vehicle control treated. Abundant 365 lamellipodia seen in the control treatment were visibly diminished in the treatment groups. 366
Comparing responses within the treatment groups, CKI disrupted the lamellipodia 367 extensions more than was seen with MN or MJ alone. The impairment of F-actin 368 polymerization was consistent with the idea that MN and MJ fractions both contribute 369 slowing cell migration. Natural compounds with anti-cancer activities have been suggested to include potential anti-393 metastatic agents (17, 21, 31, 32). Clinical chemotherapeutics for cancers are targeted 394 mainly to killing rapidly dividing cells (33), but cause serious side effects including 395 immunosuppression, hair loss and infertility, without eliminating risks of secondary 396 neoplasms (34). Non-toxic treatments to reduce metastasis as adjuncts to primary cancer 397 therapies are greatly needed. CKI increased apoptotic activity in breast cancer MCF-7 and 398 hepatocellular carcinoma HCC cell lines (17, 21). Results here showed that CKI also 399 significantly slowed cell migration and invasion, an outcome consistent with its beneficial 400 clinical effects. The complexity of TCM presents a challenge for identifying single active 401 compounds. By separating components of CKI into major and minor groups, and by adding 402 novel screens for migration and invasion into the analyses of CKI biological activity, we have 403 shown that co-application of multiple compounds was far more effective in blocking cell 404 migration than single agents alone, and that different compounds (serendipitously combined 405 in CKI) are required for activity across diverse cell types. channel shown to be upregulated in multiple cancer types (36, 37). Consistent with these 415 findings, we found matrine added to the CKI minor fraction further impaired cancer cell 416 migration ( Fig 2C) ; however, in contrast, addition of oxymatrine to the CKI minor fraction 417 did not affect the control of migration in any of the cell lines we tested. Oxysophocarpine 418 slowed metastasis of oral squamous cell carcinoma in vitro and in vivo, by altering 419 transcription factor Nrf2 and stress protein signaling pathways (38). In contrast, our results 420 showed oxysophocarpine partially reversed the inhibition of migration observed with the CKI 421 minor fraction. Work here showed that the major components trifolirhizin and adenine, not 422 previously characterized, when added to CKI minor fraction further slowed cell migration, 423
suggesting these agents merit further study as potential therapeutics, singly and in 424 combination. Not all components of CKI enhance its anti-cancer activities; for example, 425 depletion of three compounds (oxymatrine, oxysophocarpine and macrozamin) increased the 426 anti-proliferative activity of CKI (23). 427 428 Rational analysis of the differential effects of agents in a TCM mixture can benefit from 429 quantitative systems biology approaches. Transcriptomics has proven valuable for identifying 430 altered patterns of global gene expression in response to complex agents such as CKI (18). 431
Our pathway analysis of the transcriptome of CKI-treated MDA-MB-231 cells revealed a 432 strong association with genes linked to "TGF-β signaling", "focal adhesion", "GnRH 433 
